NCT05683834 2026-04-22
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
7 trialsNCT07536048 2026-04-17
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
Sanofi
Not yet recruiting
NCT00032513 2026-04-08
Genetic Studies of Chronic Active Epstein-Barr Disease
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03258567 2026-04-08
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT02135042 2026-04-03
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NCT06119256 2026-04-02
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Phase 1 Recruiting
NCT06908096 2026-03-30
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting